PET and PET/CT for response evaluation in lymphoma: Current practice and developments

Leukemia and Lymphoma

Volumn 48, Issue 2, 2007, Pages 270-282

  Brepoels, Lieselot ^a   Stroobants, Sigrid ^a   Verhoef, Gregor ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE; METHIONINE; TRIFLURIDINE; TYROSINE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG MEGADOSE; DRUG RESPONSE; FALSE POSITIVE RESULT; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; ISOTOPE LABELING; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; REVIEW; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; EVALUATION; LYMPHOMA; RADIOGRAPHY; SCINTISCANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EVALUATION STUDIES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34247855900     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601078118     Document Type: Review

References (72)

1. Aleman, B. M., Belt-Dusebout, A W van den, Klokman, W. J., Veer, M B Van't, Bartelink, H. and van Leeuwen, F. E. (2003) Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol, 21, pp. 3431-3439.
2. Ng, A. K., Bernardo, M. P., Weller, E., Backstrand, K. H., Silver, B. and Marcus, K. C. (2002) Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol, 20, pp. 2101-2108.
3. Cesare, E Di, Cerone, G., Enrici, R. M., Tombolini, V., Anselmo, P. and Masciocchi, C. (2004) MRI characterization of residual mediastinal masses in Hodgkin's disease: Long-term follow-up. Magn Reson Imaging, 22, pp. 31-38.
4. Bendini, M., Zuiani, C., Bazzocchi, M., Dalpiaz, G., Zaja, F. and Englaro, E. (1996) Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study. MAGMA, 4, pp. 213-224.
5. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
6. Reinhardt, M. J., Herkel, C., Altehoefer, C., Finke, J. and Moser, E. (2005) Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: When do we really need FDG-PET?. Ann Oncol, 16, pp. 1524-1529.
7. Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J. and Vandenberghe, P. (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol, 19, pp. 414-419.
8. Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P. and Rigo, P. (1999) Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed classical computed tomography scan imaging. Blood, 94, pp. 429-433.
9. Naumann, R., Vaic, A., Beuthien-Baumann, B., Bredow, J., Kropp, J. and Kittner, T. (2001) Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol, 115, pp. 793-800.
10. Zinzani, P. L., Fanti, S., Battista, G., Tani, M., Castellucci, P. and Stefoni, V. (2004) Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer, 91, pp. 850-854.
11. Mikhaeel, N. G., Timothy, A. R., O'Doherty, M. J., Hain, S. and Maisey, M. N. (2000) 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT. Leuk Lymphoma, 39, pp. 543-553.
12. Jerusalem, G., Hustinx, R., Beguin, Y. and Fillet, G. (2005) Evaluation of therapy for lymphoma. Semin Nucl Med, 35, pp. 186-196.
13. Eghbali, H., Brice, P., Creemers, G. Y., Kooij, van Marwijk, Carde, P. and Veer, M B Van't (2005) Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-F trial. Blood
14. Loeffler, M., Brosteanu, O., Hasenclever, D., Sextro, M., Assouline, D. and Bartolucci, A. A. (1998) Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol, 16, pp. 818-829.
15. Meyer, R. M., Gospodarowicz, M. K., Connors, J. M., Pearcey, R. G., Bezjak, A. and Wells, W. A. (2005) Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol, 23, pp. 4634-4642.
16. Hueltenschmidt, B., Sautter-Bihl, M. L., Lang, O., Maul, F. D., Fischer, J. and Mergenthaler, H. G. (2001) Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer, 91, pp. 302-310.
17. Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P. and Balzarini, J. (2001) Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?. Br J Haematol, 115, pp. 272-278.
18. Dittmann, H., Sokler, M., Kollmannsberger, C., Dohmen, B. M., Baumann, C. and Kopp, A. (2001) Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Comparison of FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep, 8, pp. 1393-1399.
19. Weihrauch, M. R., Scheidhauer, K., Ansen, S., Dietlein, M. and Bischoff, S. (2001) Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood, 98, pp. 2930-2934.
20. de Wit, M., Bohuslavizki, K. H., Buchert, R., Bumann, D., Clausen, M. and Hossfeld, D. K. (2001) 18FDG-PET following treatment as valid predictor for disease-free survival I Hodgkin's disease. Ann Oncol, 12, pp. 29-37.
21. Lavely, W. C., Delbeke, D., Greer, J. P., Morgan, D. S., Byrne, D. W. and Price, R. R. (2003) FDG PET in the follow-up management of patients with newly diagnosed Hodgkin and non-Hodgkin lymphoma after first-line chemotherapy. Int J Radiat Oncol Biol Phys, 57, pp. 307-315.
22. Guay, C., Lepine, M., Verreault, J. and Benard, F. (2003) Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med, 44, pp. 1225-1231.
23. Jerusalem, G., Beguin, Y., Fassotte, M. F., Belhocine, T., Hustinx, R. and Rigo, P. (2003) Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol, 14, pp. 123-130.
24. Friedberg, J. W., Fischman, A., Neuberg, D., Kim, H., Takvorian, T. and Ng, A. K. (2004) FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma, 45, pp. 85-92.
25. Panizo, C., Perez-Salazar, M., Bendandi, M., Rodriguez-Calvillo, M., Boan, J. F. and Garcia-Velloso, M. J. (2004) Positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual Hodgkin's disease mediastinal masses. Leuk Lymphoma, 45, pp. 1829-1833.
26. Rigacci, L., Castagnoli, A., Dini, C., Carpaneto, A., Matteini, M. and Alterini, R. (2005) 18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: Long-term results. Oncol Rep, 14, pp. 1209-1214.
27. Zijlstra, J. M., der Werf, G Lindauer-van, Hoekstra, O. S., Hooft, L., Riphagen, I. I. and Huijgens, P. C. (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: A systematic review. Haematologica, 91, pp. 522-529.
28. Castellucci, P., Nanni, C., Farsad, M., Alinari, L., Zinzani, P. and Stefoni, V. (2005) Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: Prevalence and scan interpretation. Nucl Med Commun, 26, pp. 689-694.
29. Moser, E. C., Noordijk, E. M., van Glabbeke, M., Teodorovic, I., de Wolf-Peeters, C. and Carde, P. (2004) Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials. Eur J Cancer, 40, pp. 474-480.
30. Juweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y. and Wooldridge, J. E. (2005) Response assessment of aggressive non-Hodgkin's lymphoma by Integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol, 23, pp. 4652-4661.
31. Jerusalem, G., Beguin, Y., Najjar, F., Hustinx, R., Fassotte, M. F. and Rigo, P. (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol, 12, pp. 825-830.
32. Schoder, H., Noy, A., Gonen, M., Weng, L., Green, D. and Erdi, Y. E. (2005) Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. J Clin Oncol, 23, pp. 4643-4651.
33. Wong, C. Y., Thie, J., Parling-Lynch, K. J., Zakalik, D., Margolis, J. H. and Gaskill, M. (2005) Glucose-Normalized Standardized Uptake Value from 18F-FDG PET in Classifying Lymphomas. J Nucl Med, 46, pp. 1659-1663.
34. Hoffmann, M., Kletter, K., Becherer, A., Jager, U., Chott, A. and Raderer, M. (2003) 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology, 64, pp. 336-340.
35. Palmedo, H., Urbach, H., Bender, H., Schlegel, U., Schmidt-Wolf, I. G. and Matthies, A. (2006) FDG-PET in immunocompetent patients with primary central nervous system lymphoma: Correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging, 33, pp. 164-168.
36. Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M. and Guermazi, A. (2006) Use of positron emission tomography (PET) for response assessment of lymphoma: Consensus of the imaging subcommittee of International Harmonization Project (IHP) in lymphoma. J Clin Oncol
37. Reske, S. N. (2003) PET and restaging including residual masses and relapse. Eur J Nucl Med Mol Imaging, 30, pp. S89-S96.
38. Spaepen, K., Stroobants, S., Verhoef, G. and Mortelmans, L. (2003) Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging, 30, pp. S97-S105.
39. Beal, K. P., Yeung, H. W. and Yahalom, J. (2005) FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: A report of 42 cases. Ann Oncol, 16, pp. 473-480.
40. Juweid, M., Stroobants, S., Mottaghy, F., Hoekstra, O., Guermazi, A. and Dietlein, M. Recommendations of the imaging committee of the International Harmonization Project (IHP) for FDG-PET (PET) use in patients with lymphoma. Annual congress of the European Association of Nuclear Medicine (EANM) Athens, Greece
41. Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Horning, S. J. and Coiffier, B. (2006) Revised Response Criteria for Malignant Lymphoma. J Clin Oncol
42. Gobbi, P. G., Zinzani, P. L., Broglia, C., Comelli, M., Magagnoli, M. and Federico, M. (2001) Comparison of prognostic models in patients with advanced Hodgkin's disease. Cancer, 91, pp. 1467-1478.
43. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U. and Hasenclever, D. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med, 348, pp. 2386-2395.
44. Kaiser, U., Uebelacker, I., Abel, U., Birkmann, J., Trumper, L. and Schmalenberg, H. (2002) Randomized study to evaluate the use of high-dose therapy as part of primary treatment for 'aggressive' lymphoma. J Clin Oncol, 20, pp. 4413-4419.
45. Higashi, K., Clavo, A. L. and Wahl, R. L. (1993) Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med, 34, pp. 414-419.
46. Römer, W., Hanauske, A. R., Ziegler, S., Thodtmann, R., Weber, W. and Fuchs, C. (1998) Positron emission Tomography in Non Hodgkin's Lymphoma: Assessment of chemotherapy with fluorodeoxyglucose. Blood, 91, pp. 4464-4471.
47. Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P. and Rigo, P. (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica, 85, pp. 613-618.
48. Mikhaeel, N. G., Mainwaring, P., Nunan, T. and Timothy, A. R. (2002) Prognostic value of interim and post treatment FDG-PET scanning in Hodgkin lymphoma. Ann Oncol, 13, p. 21.
49. Kostakoglu, L., Coleman, M., Leonard, J. P., Kuji, I., Zoe, H. and Goldsmith, S. J. (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med, 43, pp. 1018-1027.
50. Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J. and de Groot, T. (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol, 13, pp. 1356-1363.
51. Zijlstra, J. M., Hoekstra, O. S., Raijmakers, P. G., Comans, E. F., van der Hoeven, J. J. and Teule, G. J. (2003) 18FDG positron emission tomography versus 67Ga scintigraphy as prognostic test during chemotherapy for non-Hodgkin's lymphoma. Br J Haematol, 123, pp. 454-462.
52. Torizuka, T., Nakamura, F., Kanno, T., Futatsubashi, M., Yoshikawa, E. and Okada, H. (2004) Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging, 31, pp. 22-28.
53. Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J. D. and Belhadj, K. (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood, 106, pp. 1376-1381.
54. Mikhaeel, N. G., Hutchings, M., Fields, P. A., O'Doherty, M. J. and Timothy, A. R. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol, 16, pp. 1514-1523.
55. Hutchings, M., Mikhaeel, N. G., Fields, P. A., Nunan, T. and Timothy, A. R. (2005) Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol, 16, pp. 1160-1168.
56. Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T. and Jurlander, J. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, pp. 52-59.
57. Gallamini, A., Rigacci, L., Merli, F., Nassi, L., Bosi, A. and Capodanno, I. (2006) The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica, 91, pp. 475-481.
58. Philip, T., Guglielmi, C., Hagenbeek, A., Somers, R., Van der Lelie, H. and Bron, D. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med, 333, pp. 1540-1545.
59. Becherer, A., Mitterbauer, M., Jaeger, U., Kalhs, P., Greinix, H. T. and Karanikas, G. (2002) Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Leukemia, 16, pp. 260-267.
60. Cremerius, U., Fabry, U., Wildberger, J. E., Zimny, M., Reinartz, P. and Nowak, B. (2002) Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant, 30, pp. 103-111.
61. Filmont, J. E., Czernin, J., Yap, C., Silverman, D. H., Quon, A. and Phelps, M. E. (2003) Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest, 124, pp. 608-613.
62. Spaepen, K., Stroobants, S., Dupont, P., Thomas, J., Vandenberghe, P. and Maertens, J. (2003) Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Blood, 102, pp. 53-59.
63. Schot, B. W., Pruim, J., van Imhoff, G. W., Sluiter, W. J., Vaalburg, W. and Vellenga, E. (2006) The role of serial pre-transplantation positron emission tomography in predicting progressive disease in relapsed lymphoma. Haematologica, 91, pp. 490-495.
64. Freudenberg, L. S., Antoch, G., Schütt, P., Beyer, T., Jentzen, W. and Müller, S. P. (2004) FDG-PET/CT in restaging of patients with lymphoma. Eur J Nucl Med Mol Imaging, 3, pp. 325-329.
65. Schaefer, N. G., Hany, T. F., Taverna, C., Seifert, B., Stumpe, K. D. and von Schulthess, G. K. (2004) Non-Hodgkin's lymphoma and Hodgkin's disease: Coregistered FDG-PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology, 232, pp. 823-829.
66. Raanani, P., Shasha, Y., Perry, C., Metser, U., Naparstek, E. and Apter, S. (2006) Is CT still necessary for staging in Hodgkin and non-Hodgkin's lymphoma patients in the PET/CT era?. Ann Oncol, 17, pp. 117-122.
67. Aquino, S. L., Kuester, L. B., Muse, V. V., Halpern, E. F. and Fischman, A. J. (2006) Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging, 33, pp. 692-696.
68. Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H. J., Stayanoff, J. C. and Lawhorn-Crews, J. M. (1998) Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med, 4, pp. 1334-1336.
69. Buchmann, I., Neumaier, B., Schreckenberger, M. and Reske, S. (2004) [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: Whole-body biodistribution and imaging of lymphoma manifestations-a pilot study. Cancer Biother Radiopharm, 19, pp. 436-442.
70. Wagner, M., Seitz, U., Buck, A., Neumaier, B., Schultheiss, S. and Bangerter, M. (2003) 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res, 63, pp. 2681-2687.
71. Been, L. B., Suurmeijer, A. J., Cobben, D. C., Jager, P. L., Hoekstra, H. J. and Elsinga, P. H. (2004) [18F]FLT-PET in oncology: Current status and opportunities. Eur J Nucl Med Mol Imaging, 31, pp. 1659-1672.
72. Zhao, S., Kuge, Y., Nakada, K., Takei, T., Kohanawa, M. and Zhao, Y. 11C-Methionine but not 18F-FDG and 18F-FLT can differentiate tumor from granuloma in experimental rat models. 53rd Annual Meeting of the Society of Nuclear Medicine (SNM) San Diego, CA